The scope of this task order is (1). Production of a drug substance, (2) conversion of drug substance to drug product, (3) filling drug product into applicators to be used in the clinical trials,…
Ended Awarded Last action
- Contract number
- 75N91024F00001
- Awardee
-
Mriglobal UEI HKQHNFKNKL15
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,866,116
Award facts
- Opportunity
-
- MLACV202401 Solicitation number
- Contract value 100% obligated
- $1,866,116.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Kansas City, MO 64110, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,866,116 |
About this award
This federal contract award, with an ID of 75N91023D00010|75N91024F00001, was issued by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services. The contract, which is not set aside, has a ceiling value of $1,866,116.00 and a completion date of September 17, 2026. The scope of the contract includes the production of a drug substance, conversion of the drug substance to a drug product, filling the drug product into applicators for clinical trials, and the production of a placebo product.
The prime contractor for this award is Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization that specializes in areas such as medical countermeasure development, biosafety testing, and threat detection technologies. Mriglobal has a significant portfolio of federal contracts and grants, including a $146.3 million Indefinite Delivery Vehicle (IDV) from the National Institute of Allergy and Infectious Diseases for preclinical evaluation of infectious disease countermeasures.
Mriglobal has subcontracted a portion of the work to List Biological Laboratories, Inc., a foreign-owned, self-certified small disadvantaged business that specializes in the manufacture of biological products, particularly lipopolysaccharides, for federal agencies and clinical trials.
Description
The scope of this task order is (1). Production of a drug substance, (2) conversion of drug substance to drug product, (3) filling drug product into applicators to be used in the clinical trials, and (4) production of a placebo product.
Quick answers
Who was awarded contract 75N91024F00001?
75N91024F00001 was awarded to Mriglobal by National Cancer Institute (National Institutes of Health) on September 18, 2024.
How much is contract 75N91024F00001 worth?
The government has obligated $1,866,116 on 75N91024F00001.
Is contract 75N91024F00001 an order under another contract?
Yes. 75N91024F00001 is a delivery order under 75N91023D00010, an indefinite delivery contract.
Was contract 75N91024F00001 competed?
The extent of competition for 75N91024F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award